Trial Profile
An Open-Label Study To Assess The Clinical Benefit Of Droxidopa In Subjects With Chronic Fatigue Syndrome
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Droxidopa (Primary)
- Indications Chronic fatigue syndrome; Orthostatic hypotension
- Focus Therapeutic Use
- Sponsors Chelsea Therapeutics
- 24 Jun 2014 New trial record